Ratios

		vs industry	vs history
P/B	26.80	ALXA's P/B is ranked lower than 69% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.00 vs. ALXA: 26.80 )	ALXA' s 10-Year P/B Range Min: 1.22   Max: 36.5 Current: 26.8 1.22 36.5
P/S	11.50	ALXA's P/S is ranked lower than 85% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.32 vs. ALXA: 11.50 )	ALXA' s 10-Year P/S Range Min: 1.25   Max: 2725 Current: 11.5 1.25 2725
EV-to-EBIT	4.3	ALXA's EV-to-EBIT is ranked higher than 97% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 21.70 vs. ALXA: 4.3 )	ALXA' s 10-Year EV-to-EBIT Range Min: 2.7   Max: 12.7 Current: 4.3 2.7 12.7

Valuation & Return

		vs industry	vs history
Price/Tangible Book	26.8	ALXA's Price/Tangible Book is ranked higher than 85% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.40 vs. ALXA: 26.8 )	ALXA' s 10-Year Price/Tangible Book Range Min: 3   Max: 13 Current: 26.8 3 13
Price/Median PS Value	3.3	ALXA's Price/Median PS Value is ranked higher than 92% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.70 vs. ALXA: 3.3 )	ALXA' s 10-Year Price/Median PS Value Range Min: 0.2   Max: 26.2 Current: 3.3 0.2 26.2
Earnings Yield (Greenblatt)	23.30	ALXA's Earnings Yield (Greenblatt) is ranked higher than 96% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.90 vs. ALXA: 23.30 )	ALXA' s 10-Year Earnings Yield (Greenblatt) Range Min: 7.9   Max: 37.3 Current: 23.3 7.9 37.3

Business Description

Alexza Pharmaceuticals, Inc. was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed its name to Alexza Corporation and in December 2001 the company became Alexza Molecular Delivery Corporation. In July 2005, it changed its name to Alexza Pharmaceuticals, Inc. The company is a pharmaceutical development company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system or CNS conditions. Alexza's primary activities since incorporation have been establishing its offices, recruiting personnel, conducting research and development, conducting preclinical studies and clinical trials, performing business and financial planning, and raising capital. Accordingly, the company is considered to be in the development stage and operates in one business segment. Alexza currently has six product candidates in various stages of clinical development, ranging from Phase 1 through late-stage Phase 3. The company has screened more than 400 drug compounds, identifying approximately 200 drug compounds that demonstrate initial vaporization feasibility for delivery with its technology. Alexza is initially focusing on developing proprietary products by combining its Staccato system with small molecule drugs that have been in use for many years and are well characterized to create aerosolized forms of these drugs. The company's clinical-stage product candidates are: AZ-004 or Staccato loxapine: It is developing AZ-004 for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. Alexza project a new drug application, or NDA, submission in the first quarter of 2010. AZ-004 has been licensed to Symphony Allegro, Inc. AZ-104 or Staccato loxapine: Alexza is developing AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower-dose version of AZ-004. AZ-104 has completed a Phase 2a in-clinic study in migraine patients. AZ-001 or Staccato prochlorperazine: The Company is developing AZ-001 to treat patients suffering from acute migraine headaches. AZ-007 or Staccato zaleplon: Alexza is developing AZ-007 for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. The company has completed and announced positive results from a Phase 1 clinical trial of AZ-007. AZ-003 or Staccato fentanyl: Alexza is developing AZ-003 for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes.
Company Website
SEC Reports

Industry:	Drug Manufacturers - Specialty & Generic
Compare:	TKPYY, TEVA, AGN, FRX, MRX

» More Articles for ALXA

Headlines

Articles On GuruFocus.com

Alexza Pharmaceuticals Inc. (ALXA) SVP, CFO & Sec August J Moretti sells 10,000 Shares May 07 2010

Alexza Pharmaceuticals Inc. (ALXA) SVP, CFO & Sec August J Moretti sells 14,000 Shares Dec 21 2009

Alexza Pharmaceuticals Inc. (ALXA) Pres & CEO Thomas Braxton King sells 45,000 Shares Dec 21 2009

Weekly CEO Buy Highlight: Winmark Corp, Alexza Pharmaceuticals Inc, Ladenburg Thalmann Financial Ser Oct 11 2009

Personalized Checklist